Back to search
FDAFDA · Food and drugs·Recall number D-1354-2022

Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL single dose vials, Rx Only, Nephron Pharmaceutical Corporation 4500 12th Street Extension West Columbia, SV 29172, NDC 0487-6232-01

Published August 24, 2022 · Recall initiated: August 10, 2022

Summary

FDA records drug Class II recall D-1354-2022, published August 24, 2022 and initiated August 10, 2022. Recalling firm: Nephron Sc Inc; Status: Terminated; Reported quantity: 5040 vials; Lot: Lot#: 023011 Exp 8/31/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations: deviations leading to potential cross-contamination.

What to do

Voluntary: Firm initiated · Letter

Get an email if KETOROLAC TROMETHAMINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
KETOROLAC TROMETHAMINE
Manufacturer
Nephron Sc Inc
Distributor
USA Nationwide
Lot
Lot#: 023011 Exp 8/31/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL single dose vials, Rx Only, Nephron Pharmaceutical Corporation 4500 12th Street Extension West Columbia, SV 29172, NDC 0487-6232-01 recalled?

Yes. FDA published recall D-1354-2022 on August 24, 2022. Reported hazard: cGMP Deviations: deviations leading to potential cross-contamination.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: KETOROLAC TROMETHAMINE.